SF
ALXN

Synovus Financial’s Alexion Pharmaceuticals ALXN Stock Holding History

Synovus Financial’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,694
Closed -$417K – 804
2020
Q4 		$417K Buy
2,694
+119
+5% +$15.3K ﹤0.01% 583
2020
Q3 		$292K Sell
2,575
-130
-5% -$14K ﹤0.01% 607
2020
Q2 		$304K Sell
2,705
-3,364
-55% -$357K ﹤0.01% 577
2020
Q1 		$559K Buy
6,069
+3,585
+144% +$352K 0.01% 494
2019
Q4 		$267K Buy
2,484
+93
+4% +$9.95K ﹤0.01% 617
2019
Q3 		$230K Buy
2,391
+106
+5% +$11.9K ﹤0.01% 630
2019
Q2 		$302K Buy
2,285
+83
+4% +$10.7K ﹤0.01% 539
2019
Q1 		$298K Buy
2,202
+1,678
+320% +$209K ﹤0.01% 521
2018
Q4 		$52K Buy
524
+65
+14% +$7.68K ﹤0.01% 786
2018
Q3 		$63K Buy
459
+353
+333% +$44.3K ﹤0.01% 783
2018
Q2 		$13K Hold
106
– – ﹤0.01% 1025
2018
Q1 		$12K Sell
106
-2,002
-95% -$239K ﹤0.01% 1017
2017
Q4 		$252K Buy
2,108
+61
+3% +$7.43K ﹤0.01% 529
2017
Q3 		$290K Sell
2,047
-13,190
-87% -$1.79M 0.01% 484
2017
Q2 		$1.85M Sell
15,237
-549
-3% -$63.9K 0.04% 198
2017
Q1 		$1.91M Buy
15,786
+701
+5% +$90.4K 0.04% 180
2016
Q4 		$1.85M Sell
15,085
-1,024
-6% -$125K 0.04% 177
2016
Q3 		$1.98M Buy
16,109
+442
+3% +$56.9K 0.05% 166
2016
Q2 		$1.83M Buy
15,667
+4,421
+39% +$627K 0.04% 177
2016
Q1 		$1.57M Buy
11,246
+10,420
+1,262% +$1.53M 0.04% 193
2015
Q4 		$157K Buy
826
+815
+7,409% +$142K ﹤0.01% 483
2015
Q3 		$2K Sell
11
-38
-78% -$6.93K ﹤0.01% 929
2015
Q2 		$9K Sell
49
-94
-66% -$16.2K ﹤0.01% 856
2015
Q1 		$24K Hold
143
– – ﹤0.01% 742
2014
Q4 		$26K Hold
143
– – ﹤0.01% 729
2014
Q3 		$24K Hold
143
– – ﹤0.01% 716
2014
Q2 		$23K Hold
143
– – ﹤0.01% 689
2014
Q1 		$21K Buy
+143
New +$22.7K ﹤0.01% 701

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Synovus Financial's ALXN Position: Q1 2021 in Review

Synovus Financial sold out of Alexion Pharmaceuticals (ALXN) in Q1 2021, closing a stake of 2,694 shares — an estimated $417K sold.

Synovus Financial first reported a position in ALXN in Q1 2014 and held it in 28 quarters. The position peaked at $1.98M in Q3 2016. 754 funds tracked by Wall St. Rank hold ALXN as of Q1 2021.

  • Synovus Financial reported no remaining Alexion Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Synovus Financial sold 2,694 Alexion Pharmaceuticals shares in Q1 2021, an estimated $417K.
  • Synovus Financial first reported a position in Alexion Pharmaceuticals in Q1 2014 and held it in 28 quarters.
  • Synovus Financial's Alexion Pharmaceuticals position peaked at $1.98M in Q3 2016.
  • 754 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q1 2021.

Based on Synovus Financial's 13F filing for Q1 2021, filed 11 May 2021.